CD4 and Bone marrow hypocellularity: Our results indicated that Coptidis alkaloid treatment could interfere with the differentiation of CD4+ T cells, deplete the expansion of Th1 and Th17 cells, augment the proportions of Th2 and Treg cells, and reduce the severity of bone marrow failure mediated by immune destruction.